erlotinib hydrochloride has been researched along with ponatinib in 2 studies
Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (ponatinib) | Trials (ponatinib) | Recent Studies (post-2010) (ponatinib) |
---|---|---|---|---|---|
4,353 | 786 | 3,033 | 538 | 34 | 519 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Adkins, J; Aldrich, J; Asmann, Y; Baker, A; Barr Fritcher, EG; Barrett, MT; Bhavsar, JD; Bible, KC; Block, M; Borad, MJ; Bryce, AH; Carpten, JD; Champion, MD; Cherni, I; Christoforides, A; Collins, JM; Condjella, RM; Craig, DW; Egan, JB; Fonseca, R; Han, H; Harris, P; Hunt, K; Izatt, T; Kipp, BR; Klee, EW; Kocher, JP; Kurdoglu, A; Lazaridis, KN; Liang, WS; Lobello, J; Mastrian, SD; McCullough, AE; McDonald, J; McWilliams, RR; Middha, S; Nair, AA; Nasser, S; Oliver, GR; Patel, MD; Phillips, L; Placek, P; Reiman, R; Schahl, K; Silva, AC; Stewart, AK; Von Hoff, D; Watanabe, AT; Young, SW | 1 |
Cao, Y; Du, P; Kim, HJ; Lee, HJ; Settleman, J; Zhuang, G | 1 |
2 other study(ies) available for erlotinib hydrochloride and ponatinib
Article | Year |
---|---|
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Genome, Human; Humans; Imidazoles; Indazoles; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Transcriptome | 2014 |
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Interleukin-6; Janus Kinase 1; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mice, SCID; Mutation; Nitriles; Oncogenes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; ras Proteins; Receptors, Fibroblast Growth Factor; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2014 |